N4BP2: A Potential Drug Target and Biomarker (G55728)

Target Name: N4BP2

NCBI ID: G55728

N4BP2

N4BP2: A Potential Drug Target and Biomarker

NEDD4 (N-Acetyl-L-Aspartate-Sulfokinase) binding protein 2 (N4BP2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. N4BP2 is a key enzyme in the detoxification of N-acetyl-L-aspartate (N-ASP), a potentially toxic compound that can accumulate in the brain and contribute to the development of neurodegenerative diseases. The inhibition of N4BP2 has been shown to have therapeutic benefits in animal models of neurodegenerative diseases, including stroke, Alzheimer's disease, and Parkinson's disease.

The N4BP2 gene was identified through a combination of genomic and biochemical approaches. The gene was found to be located on chromosome 6p21.2 and encodes a protein with 218 amino acid residues. N4BP2 is predominantly localized to the endoplasmic reticulum (ER) and nuclear specimen, and its concentration in the cytoplasm is relatively low. The protein has a calculated pI of 9.95 and a predicted localization in the ER.

N4BP2 functions as an enzyme that catalyzes the detoxification of N-ASP, a potent antioxidant that can contribute to the development of neurodegenerative diseases. N-ASP is a byproduct of cellular metabolism and can accumulate in the brain due to various factors, including aging, oxidative stress, and neurotoxins. The accumulation of N-ASP in the brain can lead to the formation of N-ASP-rich aggregates, which are toxic to neurons and contribute to the development of neurodegenerative diseases.

The N4BP2 enzyme has been shown to play a crucial role in the detoxification of N-ASP in the brain. N4BP2 has been shown to decrease the level of N-ASP in the brain and protect against the formation of N-ASP-rich aggregates. In animal models of neurodegenerative diseases, the inhibition of N4BP2 has been shown to improve cognitive function, reduce neurotoxicity, and delay the progression of disease.

In addition to its role in the detoxification of N-ASP, N4BP2 has also been shown to have other functions that are relevant to neurodegenerative diseases. N4BP2 has been shown to play a role in the regulation of cellular stress responses, and it has been shown to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. N4BP2 has also been shown to play a role in the regulation of mitochondrial function, and it has been shown to interact with various cellular processes that are involved in mitochondrial function, including energy metabolism and stress response.

The potential utility of N4BP2 as a drug target or biomarker for neurodegenerative diseases is significant. The inhibition of N4BP2 has been shown to have therapeutic benefits in animal models of neurodegenerative diseases, including stroke, Alzheimer's disease, and Parkinson's disease. The potential clinical applications of N4BP2 as a drug target or biomarker are vast, and further research is needed to fully understand its role in the development and treatment of neurodegenerative diseases.

In conclusion, N4BP2 is a protein that has been identified as a potential drug target and biomarker for various neurodegenerative diseases. The inhibition of N4BP2 has been shown to have therapeutic benefits in animal models of neurodegenerative diseases, and further research is needed to fully understand its role in the development and treatment of these diseases.

Protein Name: NEDD4 Binding Protein 2

Functions: Has 5'-polynucleotide kinase and nicking endonuclease activity. May play a role in DNA repair or recombination

The "N4BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about N4BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets